Mounjaro is a highly effective, UK-licensed weight loss treatment, clinically proven to help achieve approximately 20% body weight reduction. It is the latest GLP-1 weight loss injection, suitable for individuals with a body mass index (BMI) over 30, or those with a BMI of 27 who have a weight-related medical condition.
The active ingredient in Mounjaro is Tirzepatide, and it is a registered trademark of Eli Lilly. In the US, it is marketed as Zepbound, but it is known as Mounjaro in the UK.
Mounjaro is administered once weekly as a subcutaneous (under the skin) injection. It can be injected into the abdomen, thigh, or upper arm at any time of day, with or without food. For optimal effectiveness, it is recommended to use the injection at the same time each week. Detailed instructions on how to inject Mounjaro can be found in the Patient Information Leaflet provided with your medication.
Your first order will include clear guidance, and additional resources are available on the official Mounjaro website.
More information on how to inject Mounjaro can be found in the Patient Information Leaflet.